Nuclear Imaging

Molecular imaging, also called nuclear imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI.

Patients underwent BNCT using TAE Life Sciences’ Neutron Beam System as part of Neuboron Medical Group’s NeuPex System at Xiamen Humanity Hospital in China

News | Radiation Therapy

TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)

February 16, 2023 — TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation ...

February 16, 2023

First dosage administered at the Hospital of the University of Pennsylvania following FDA approval

News | Contrast Media

Guerbet Announces Commercial Launch and First Patient Dosing of Elucirem (Gadopiclenol) Injection

February 16, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced ...

February 16, 2023

The FDA has identified this as a Class I recall, the most serious type of recall

News | Nuclear Imaging

GE HealthCare Recalls Nuclear Medicine 600/800 Series Systems for Risk of Detector Fall That May Injure Patients

February 23, 2023 — Editor's note: This news item has been updated to reflect that the FDA has since updated its alert ...

February 15, 2023

Sponsored Content

Staging F-18 FDG PET/CT images of adenocarcinoma in the RUL of the lung illustrates the value of Vereos. The primary lesion in the right upper lobe appears in the upper row (PET image is left, CT image is right). A 3 mm synchronous primary or metastatic lesion in the RUL is apparent in the lower row. The precision afforded by Vereos' images provided the basis for the patient to undergo RUL lobectomy instead of thermal ablation of the primary lesion. Images courtesy of Dr. Jay Kikut and UVM

Blog | PET-CT

Digital PET Balances Scan Time and Resolution

Efficiency and effectiveness are inseparable in clinical medicine. Digital PET addresses them both. The key is the ...

October 25, 2018

Requiring half the gadolinium dosage compared to other macrocyclic gadolinium-based contrast agents (GBCAs) in approved indications in the U.S., gadopiclenol also has the highest relaxivity compared to approved GBCAs1-7

News | Contrast Media

First Nationwide Use of Bracco's VUEWAY (gadopiclenol) Solution for Injection for MRI

February 15, 2023 — Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a ...

February 15, 2023

18F-rhPSMA-7.3 PET image showing multiple areas of uptake in the prostate gland in a man with newly diagnosed prostate cancer Photo courtesy of Blue Earth Diagnostics

News | Prostate Cancer

Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study

February 9, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

February 09, 2023

Moffitt Cancer Center at International Plaza

News | Proton Therapy

IBA Announces Contract with Moffitt Cancer Center for a Proteus ONE Proton Therapy Solution

February 7, 2023 — IBA (Ion Beam Applications S.A.), a world leader in particle accelerator technology, today announces ...

February 07, 2023

News | Contrast Media

Efficacy and Safety of Gadopiclenol with Contrast-enhanced MRI of the Central Nervous System Published

February 6, 2023 — Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a ...

February 06, 2023

News | Radiology Business

Allegheny Health Network Facilities Recognized as Diagnostic Imaging Centers of Excellence by American College of Radiology

February 2, 2023 — Five additional imaging centers across Allegheny Health Network (AHN) have been recognized by the ...

February 02, 2023

Summary of the pilot study and preliminary PET imaging findings. Image created by R Wetherill, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

News | PET Imaging

PET Imaging Shows Greater Lung Inflammation in e-cigarette Users than Cigarette Smokers

January 31, 2023 — Electronic cigarette (e-cigarette) users have greater lung inflammation than cigarette smokers and ...

January 31, 2023

Summary of imaging findings from the SEER-Medicare linked database for patients with non-small cell lung cancer prior to receiving subsequent radiation therapy. Image created by Emily Sterbis, MD, Interventional Radiology Resident at the University of Colorado

News | Lung Imaging

Nearly Half of Medicare Patients with Non-small Cell Lung Cancer not Staged According to National Guidelines

January 23, 2023 — A study published in the January issue of The Journal of Nuclear Medicine reports that approximately ...

January 23, 2023

ASNC releases comprehensive tool for assessing quality, setting meaningful goals, improving patient care in SPECT MPI laboratories

News | Cardiac Imaging

New Guide Will Change How Cardiac Imagers Approach Quality Improvement

January 13, 2023 — Nuclear stress testing performed with single-photon emission computed tomography (SPECT) is the most ...

January 13, 2023

Proprietary electron accelerator technology achieves “two beams on target” milestone, validating proof of concept for large-scale U.S. Mo-99 production without the use of uranium

News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes Sets New Industry Precedent in Advancing Non-uranium based Commercial Production of Molybdenum-99 (Mo-99)

January 11, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

January 11, 2023

StreamlineMD has provided updates for 2023 Radiology and IR CPT coding, which may impact your practice’s coding, billing, and reimbursement operations.

News | Radiology Business

A Look at the Changes in 2023 to Radiology and IR CPT Codes

January 5, 2023 — StreamlineMD has provided updates for 2023 Radiology and IR CPT coding, which may impact your practice ...

January 05, 2023

This figure highlights 3 patients with a final diagnosis of low-grade uptake (Perugini grade-1). Endomyocardial biopsy results were available for the patient depicted in Panel B demonstrating ATTR-CA as the underlying pathology.

News | Molecular Imaging

Nuclear Medicine Bone Scan Study Identifies Prevalence and Outcomes of Cardiac Amyloidosis

January 5, 2023 — A new study has determined that approximately three percent of all bone scan patients have markers of ...

January 04, 2023

IBA, a world leader in particle accelerator technology, today confirms that it has signed a contract with the Spanish Ministry of Health to install ten proton therapy systems across Spain as part of a significant public tender.

News | Proton Therapy

IBA Wins 10 Proton Therapy System Contract in Spain

January 2, 2023 — IBA, a world leader in particle accelerator technology, today confirms that it has signed a contract ...

January 02, 2023

Patients for Safer Nuclear Medicine calls NRC ruling a victory, notes work to protect patients is not over

News | Nuclear Imaging

Patient Coalition Applauds Federal Decision Impacting Nuclear Medicine Safety

January 2, 2023 — The federal agency that oversees the administration of nuclear medicine has announced that it will ...

January 02, 2023

Abhinav Jha to develop technique, test in patients with metastatic prostate cancer

News | Radiation Therapy

Imaging Technique May Measure Absorbed Dose from Radiation Therapy

December 22, 2022 — Patients with cancer that has spread to the bone are sometimes treated with alpha particle radiation ...

December 22, 2022

data showed that CytoSite’s Granzyme B (GzmB) PET imaging using [68Ga-NOTA]-hGZP (CSB-111) was feasible and safe in human subjects. These data come from a Phase I trial assessing the safety and feasibility of GzmB PET imaging in subjects with melanoma and non-small cell lung cancer (NSCLC) receiving KEYTRUDA (pembrolizumab).

News | Clinical Trials

CytoSite Bio Presents First-in-Human Data at Radiological Society of North American Annual Meeting

December 14, 2022 — CytoSite Bio, a company developing precision imaging products that determine patient response to ...

December 14, 2022

News | Prostate Cancer

Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer

December 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

December 02, 2022

A team led by UTHealth Houston's K. Lance Gould, MD, (center) used PET imaging technology (shown above) to map coronary blood flow and its outcomes among heart disease patients. (Photo by UTHealth Houston)

News | PET Imaging

PET Technology More Effective Than Angiogram at Determining Need for Coronary Stents, Bypass Surgery

December 1, 2022 — A new method for determining whether patients with heart disease need coronary stents or bypass ...

December 01, 2022